ACORN CAPITAL ADVISORS, LLC
Top Portfolio Positions
21 positions ·
$350,733,296 total
· as of Mar 31, 2026
| Ticker | Company | Shares | Value (USD) | % of Portfolio | Open |
|---|---|---|---|---|---|
| TERN |
Terns Pharmaceuticals, Inc.
Healthcare
|
1,746,264 | $92,063,038 | 26.25% | |
| CGON |
CG Oncology, Inc.
Healthcare
|
1,130,501 | $76,512,307 | 21.81% | |
| URGN |
UroGen Pharma Ltd.
Healthcare
|
1,673,420 | $30,088,091 | 8.58% | |
| PBYI |
Puma Biotechnology, Inc.
Healthcare
|
4,131,299 | $26,399,000 | 7.53% | |
| TRVI |
Trevi Therapeutics, Inc.
Healthcare
|
2,144,844 | $25,587,988 | 7.30% | |
| CADL |
Candel Therapeutics, Inc.
Healthcare
|
3,497,948 | $17,139,945 | 4.89% | |
| BCAX |
Bicara Therapeutics Inc.
Healthcare
|
643,382 | $12,796,867 | 3.65% | |
| OKUR |
OnKure Therapeutics, Inc.
Healthcare
|
2,839,674 | $11,756,250 | 3.35% | |
| JBIO |
Jade Biosciences, Inc.
Healthcare
|
786,760 | $11,053,978 | 3.15% | |
| TARA |
Protara Therapeutics, Inc.
Healthcare
|
1,752,115 | $9,128,519 | 2.60% |
Portfolio Trend
6 quarters · across all stocks
Holdings in URGN
Shares Held
Position Value (USD)
6 quarters on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $30,088,091 | 1,673,420 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $33,921,996 | 1,448,420 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $25,131,992 | 1,259,749 | Shares | Sole | 2025-11-17 | |
| 2025-06-30 | $17,258,561 | 1,259,749 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $16,770,311 | 1,516,303 | Shares | Sole | 2025-05-19 | |
| 2024-12-31 | $16,148,626 | 1,516,303 | Shares | Sole | 2025-05-19 | |
| No 13F history on record for this holder in this stock. | ||||||